Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
|
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [31] Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : E181 - E182
  • [32] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [33] Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Cutsem, Eric Van
    Elez, Elena
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Liposits, Gabor
    Bondarenko, Igor
    Modest, Dominik P.
    Amellal, Nadia
    Tabernero, Josep
    FUTURE ONCOLOGY, 2024, 20 (36) : 2823 - 2832
  • [34] Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
    Garcia-Alfonso, Pilar
    Munoz, Andres
    Jimenez-Castro, Jeronimo
    Jimenez-Fonseca, Paula
    Pericay, Carles
    Longo-Munoz, Federico
    Reyna-Fortes, Carmen
    Argiles-Martinez, Guillem
    Gonzalez-Astorga, Beatriz
    Jose Gomez-Reina, Maria
    Ruiz-Casado, Ana
    Rodriguez-Salas, Nuria
    Lopez-Lopez, Rafael
    Carmona-Bayonas, Alberto
    Conde-Herrero, Veronica
    Aranda, Enrique
    CANCERS, 2021, 13 (18)
  • [35] Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil
    Avino Tarazona, V.
    Rodriguez Garces, M.
    Amor Urbano, M.
    Bolanos Naranjo, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S140 - S140
  • [36] Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Cheung, W. Y.
    Kavan, P.
    Dolley, A.
    CURRENT ONCOLOGY, 2020, 27 (05) : E451 - E458
  • [37] Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
    Patel, Anuj K.
    Barghout, Victoria
    Yenikomshian, Mihran A.
    Germain, Guillaume
    Jacques, Philippe
    Laliberte, Francois
    Duh, Mei S.
    ONCOLOGIST, 2020, 25 (01): : E75 - E84
  • [38] Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
    Ozet, Ahmet
    Dane, Faysal
    Aykan, Nuri Faruk
    Yalcin, Suayib
    Evrensel, Turkkan
    Ozkan, Metin
    Karabulut, Bulent
    Ormeci, Merve Nur
    Atasev, Ozan
    Vidot, Loick
    Cicin, Irfan
    FUTURE ONCOLOGY, 2022, 18 (29) : 3267 - 3276
  • [39] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
    Victorino, Ana Paula Ornellas S.
    Meton, Fernando
    Mardegan, Luciana
    Festa, Juliana
    Piranda, Diogo N.
    Araujo, Kelly Borges
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
  • [40] Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.
    Coutzac, Clelia
    Trouilloud, Isabelle
    Artru, Pascal
    Henriques, Julie
    Masson, Therese
    De La Fouchardiere, Christelle
    Doat, Solene
    Bouche, Olivier
    Coriat, Romain
    Saint, Angelique
    Moulin, Valerie
    Vernerey, Dewi
    Tougeron, David
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)